Ixmyelocel-T
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Critical Limb Ischemia
Conditions
Critical Limb Ischemia
Trial Timeline
Feb 1, 2012 → Mar 25, 2014
NCT ID
NCT01483898About Ixmyelocel-T
Ixmyelocel-T is a phase 3 stage product being developed by Vericel for Critical Limb Ischemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01483898. Target conditions include Critical Limb Ischemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01670981 | Phase 2 | Completed |
| NCT01483898 | Phase 3 | Completed |
| NCT01020968 | Phase 2 | Completed |
| NCT00765518 | Phase 2 | Completed |
| NCT00505219 | Phase 3 | Completed |
Competing Products
13 competing products in Critical Limb Ischemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Daptomycin | Merck | Approved | 85 |
| Ceftolozane/Tazobactam - Multiple Doses + Ceftolozane/Tazobactam - Single Dose | Merck | Phase 1 | 33 |
| Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months. | Amgen | Approved | 84 |
| intensive insulin therapy to maintain normoglycemia | Novo Nordisk | Phase 2 | 51 |
| Midazolam + Dexmedetomidine | Pfizer | Pre-clinical | 22 |
| Apixaban + ASA + Clopidogrel 75mg | Pfizer | Phase 3 | 76 |
| Colchicine (Colcrys®) + placebo + allopurinol | Regeneron Pharmaceuticals | Approved | 84 |
| Rilonacept 80 mg + Rilonacept 160 mg | Regeneron Pharmaceuticals | Phase 3 | 76 |
| treprostinil dienthanolmine sustained release + Placebo | United Therapeutics | Phase 2 | 49 |
| Remodulin® (treprostinil sodium) Injection | United Therapeutics | Phase 3 | 74 |
| Olimel (5.7%E / N9E) | Baxter | Phase 3 | 74 |
| Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E | Baxter | Approved | 82 |
| RJX + Placebo | ICON plc. | Phase 1 | 30 |